Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of GHK-Cu and NAD+ — mechanism, dosing, side effects, legal status, and pricing.
GHK-Cu is the copper(II) complex of the human tripeptide glycyl-L-histidyl-L-lysine, first identified in human plasma by Loren Pickart in 1973. Plasma GHK declines with age. It is best established as a topical cosmetic ingredient for photoaged skin; it is NOT an FDA-approved drug in any jurisdiction.
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in all living cells, not a peptide. It is classified here alongside peptides for user convenience in the anti-aging / metabolic category. NAD+ plays a central role in cellular energy metabolism and redox reactions and is studied for its involvement in mitochondrial function, DNA-damage signaling via sirtuins and PARPs, and age-associated metabolic decline. IV NAD+ is not FDA-approved for any clinical indication; it is administered off-label through compounding pharmacies and functional-medicine clinics with limited rigorous outcome data.
GHK-Cu
NAD+
Category
Legal Status
Mechanism
Dose Range
Route
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
GHK-Cu
NAD+
COA corpus from Disclosed Labs — independently tested batches only.
GHK-Cu
215
COAs
99.6%
Avg purity
17
Labs
NAD+
146
COAs
99.4%
Avg purity
15
Labs
GHK-Cu is among peptides under FDA review for the Category 1 (503A) list; if added, it would require a prescription to be compounded by registered 503A/503B pharmacies — not yet authorized. NAD+ remains research-only. In April 2026 the FDA removed 12 peptides from Category 2, which does not place them on the Category 1 list or authorize compounding. The FDA's Pharmacy Compounding Advisory Committee is advisory and meets July 23–24, 2026 to review nominations and make recommendations to the FDA.
GHK was identified in human plasma by Pickart in 1973 and characterized as a copper-binding tripeptide in Nature in 1980 (PMID 7453802). Controlled topical studies in photoaged human skin have shown improvements in skin appearance and density with ~2% formulations. Pickart's 2014 review 'GHK and DNA: resetting the human genome to health' (PMID 25302294) and 2018 Int J Mol Sci review 'Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data' (PMID 29986520) summarize transcriptomic data showing modulation of thousands of genes involved in tissue repair, DNA repair, antioxidant defense, and anti-inflammation. The SubQ protocols circulating in the peptide community (typically 1-2 mg) are not supported by controlled human trials.
Key references
The strongest human evidence for raising circulating NAD+ comes from oral-precursor trials. A randomized, double-blind, placebo-controlled study of nicotinamide riboside combined with pterostilbene (NRPT) showed sustained dose-dependent increases in whole-blood NAD+ over 8 weeks in healthy adults (Dellinger et al., npj Aging and Mechanisms of Disease, 2017). A Yoshino/Baur/Imai review summarizes the biology and emerging therapeutic potential of NR and NMN, including preclinical healthspan data in aged mice (Cell Metabolism, 2018). Direct IV NAD+ has only small pilot pharmacokinetic data: Grant et al. infused 750 mg over 6 hours in 8 healthy men and documented altered plasma and urine NAD+ metabolome without clinical-outcome endpoints (Frontiers in Aging Neuroscience, 2019). No adequately powered RCTs support IV or SubQ NAD+ for anti-aging, cognition, addiction, or Parkinson's disease; clinic marketing claims outrun the published outcome evidence.
GHK-Cu (Cosmetic) and NAD+ (Metabolic) are in different categories and target different biological pathways. This is a common pattern in multi-compound research protocols. Researchers should monitor the biomarkers from both profiles and watch for interactions listed in each compound’s contraindications. Consult a licensed healthcare provider before combining any research compounds.
Cheapest verified GHK-Cu: live prices, vendors & COA data
The cheapest verified GHK-Cu by price-per-mg — a live board of in-stock vendors with COAs on file. Lab data from 17 labs across 219 COAs.
Cheapest verified NAD+: live prices, vendors & COA data
The cheapest verified NAD+ by price-per-mg — a live board of in-stock vendors with COAs on file. Lab data from 15 labs across 158 COAs.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Frequency
Dosing Notes
Half-life
Side Effects
Contraindications
Lab Testing
Key references
Disclosed Labs